-+ 0.00%
-+ 0.00%
-+ 0.00%

Psyence Biomedical management commentary attributes higher R&D costs in six months ended September 30, 2026 to Phase IIb trial progress

PUBT·11/19/2026 13:08:05
Psyence Biomedical management commentary attributes higher R&D costs in six months ended September 30, 2026 to Phase IIb trial progress
  • Psyence Biomedical's management commentary reported a narrower net loss of USD 1.94 million for the six months ended September 30, 2026.
  • Management attributed higher research spending of USD 890,254 to progress in the Australian Phase IIb study, including patient recruitment and dosing.
  • Insurance recoveries contributed USD 424,695 to other income; higher invested cash balances lifted interest income to USD 362,187.
  • Lower legal spending reflected fewer corporate transactions, while cost discipline reduced general and administrative expenses to USD 320,000.
  • Cash, including restricted cash, reached USD 21.14 million, supported by USD 16.78 million in net common-share issuance proceeds under the ELOC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-122017), on November 19, 2026, and is solely responsible for the information contained therein.